Published in J Virol on August 22, 2007
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A (2007) 1.71
Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem (2008) 1.28
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
Identification and characterization of inhibitors of West Nile virus. Antiviral Res (2009) 1.00
Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother (2009) 0.88
Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice. J Med Virol (2008) 0.87
A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development. J Biomol Screen (2011) 0.85
West Nile virus drug discovery. Viruses (2013) 0.82
Design, synthesis, and in vitro evaluation of potential West Nile virus protease inhibitors based on the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-dihydroisoquinoline scaffolds. J Comb Chem (2010) 0.81
Generation of West Nile virus infectious clones containing amino acid insertions between capsid and capsid anchor. Viruses (2014) 0.81
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother (2014) 0.79
A Drosophila toolkit for the visualization and quantification of viral replication launched from transgenic genomes. PLoS One (2014) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Efficient initiation of HCV RNA replication in cell culture. Science (2000) 15.12
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Product review. New mammalian expression vectors. Nature (1990) 7.97
West Nile fever--a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis (1999) 7.50
Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis (2005) 6.09
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis (2002) 4.69
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. J Clin Microbiol (2000) 4.00
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis (2003) 3.52
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
West Nile virus: where are we now? Lancet Infect Dis (2004) 3.49
Genetic and phenotypic variation of West Nile virus in New York, 2000-2003. Am J Trop Med Hyg (2004) 3.34
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis (2005) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol (2005) 3.08
Partial genetic characterization of West Nile virus strains, New York State, 2000. Emerg Infect Dis (2001) 2.82
West Nile virus. JAMA (2003) 2.76
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol (2000) 2.49
Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 2.44
Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci U S A (1998) 2.44
West Nile virus neuroinvasive disease. Ann Neurol (2006) 2.42
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J Virol (2004) 2.37
Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol (2005) 2.37
Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis (2001) 2.34
Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med (2005) 2.32
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol (2003) 2.25
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J Virol (2004) 2.01
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci (2004) 1.95
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology (2001) 1.87
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology (2002) 1.81
Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis (2002) 1.75
Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol (2005) 1.75
High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother (2005) 1.73
Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother (2006) 1.72
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res (2002) 1.71
Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis (1989) 1.65
West Nile virus antibodies in Colombian horses. Emerg Infect Dis (2005) 1.65
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother (2004) 1.60
Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother (2000) 1.58
Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis (2001) 1.56
A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med (2006) 1.55
Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis (2000) 1.52
Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res (2003) 1.49
Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol (1967) 1.47
Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J (2005) 1.41
Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis (2002) 1.34
Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol (2006) 1.30
Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology (2005) 1.26
The utility of siRNA transcripts produced by RNA polymerase i in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology (2003) 1.25
Use of RNA interference to prevent lethal murine west nile virus infection. J Infect Dis (2005) 1.24
NS1 protein secretion during the acute phase of West Nile virus infection. J Virol (2005) 1.22
Actively replicating West Nile virus is resistant to cytoplasmic delivery of siRNA. Virol J (2005) 1.21
Identification of compounds with anti-West Nile Virus activity. J Med Chem (2006) 1.19
Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. Clin Infect Dis (2005) 1.17
Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J Neurovirol (2006) 1.15
Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res (2005) 1.08
Antiviral peptides targeting the west nile virus envelope protein. J Virol (2006) 1.08
The hepatitis C virus internal ribosome-entry site: a new target for antiviral research. Biochem Soc Trans (2002) 1.02
Viral translation is coupled to transcription in Sindbis virus-infected cells. J Virol (2007) 1.01
Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. Antimicrob Agents Chemother (2002) 0.98
Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. J Infect Dis (2004) 0.96
Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res (1999) 0.94
Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. Antiviral Res (2005) 0.91
Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob Agents Chemother (1983) 0.88
Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res (2006) 0.87
Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res (1990) 0.85
Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res (2005) 0.83
Combinations of nucleoside/nucleotide analogues for HIV therapy. AIDS Rev (2005) 0.82
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 8.52
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron (2005) 4.87
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci U S A (2009) 4.46
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Hrs regulates endosome membrane invagination and tyrosine kinase receptor signaling in Drosophila. Cell (2002) 3.72
Genetic analysis of cavefish reveals molecular convergence in the evolution of albinism. Nat Genet (2005) 3.66
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
The v-ATPase V0 subunit a1 is required for a late step in synaptic vesicle exocytosis in Drosophila. Cell (2005) 3.05
Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development (2004) 3.03
Mitoferrin is essential for erythroid iron assimilation. Nature (2006) 2.99
Synaptojanin is recruited by endophilin to promote synaptic vesicle uncoating. Neuron (2003) 2.96
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
The cdx genes and retinoic acid control the positioning and segmentation of the zebrafish pronephros. PLoS Genet (2007) 2.85
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
RNA-mediated epigenetic programming of a genome-rearrangement pathway. Nature (2007) 2.79
Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol (2006) 2.70
Manipulating surface states in topological insulator nanoribbons. Nat Nanotechnol (2011) 2.70
Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol (2003) 2.69
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis (2008) 2.69
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release. Cell (2002) 2.43
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
The zinc finger transcription factor Gfi1, implicated in lymphomagenesis, is required for inner ear hair cell differentiation and survival. Development (2003) 2.38
Mutations in Drosophila sec15 reveal a function in neuronal targeting for a subset of exocyst components. Neuron (2005) 2.33
TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell (2010) 2.33
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy. Ophthalmology (2011) 2.23
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A (2005) 2.19
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Mutant-specific gene programs in the zebrafish. Blood (2005) 2.15
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
The Oxytricha trifallax macronuclear genome: a complex eukaryotic genome with 16,000 tiny chromosomes. PLoS Biol (2013) 2.08
Long-term seizure, cognitive, and psychiatric outcome following trans-middle temporal gyrus amygdalohippocampectomy and standard temporal lobectomy. J Neurosurg (2013) 2.04
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog (2009) 1.95
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol (2008) 1.92
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Measuring behavioral and endocrine responses to novelty stress in adult zebrafish. Nat Protoc (2010) 1.90
Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol (2007) 1.89
Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol (2010) 1.88
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 1.84
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
A viral RNA structural element alters host recognition of nonself RNA. Science (2014) 1.71